Peak Pharmaceutical Becomes National Intellectual Property Demonstration Enterprise
Release time:
2020-08-14
Achieve "Jumping" in One Year to Fill in the Blank of Jinhua City
Peak Pharmaceutical Industry Becomes National Intellectual Property Demonstration Enterprise
It is only one year since was identified as a national intellectual property advantage enterprise in 2016 , "Zhejiang Jianfeng Pharmaceutical Co., Ltd." has appeared in the list of national intellectual property demonstration enterprises in the year 2017 recently announced by the State Intellectual Property Office. As a result, Jianfeng Pharmaceutical has become the first and only national intellectual property demonstration enterprise in Jinhua City.
12 September 12 , the State Intellectual Property Office issued a notice to announce the list of national intellectual property demonstration enterprises and advantageous enterprises in 2017 . After enterprise declaration, recommendation by provincial and municipal bureaus, examination by national bureaus, and public announcement, 182 national intellectual property demonstration enterprises and 816 national intellectual property advantage enterprises have been identified. Including Jianfeng Pharmaceutical, Zhejiang Province has been identified as a national intellectual property demonstration enterprise only 15 .
With the continuous development of enterprises in recent years, Pinnacle Pharmaceutical has set up a special working organization to cultivate and enhance intellectual property capabilities in terms of strategic management, creation, operation and protection of intellectual property rights, it has successively compiled and implemented 27 procedural documents and 36 forms such as "Intellectual Property Management Manual", "Intellectual Property Reward and Punishment System" and "Trade Secret Management System", and revised them in time according to policies and the current situation of enterprises to ensure the compliance and effectiveness of system operation. In 2012 and in 2013 , Jianfeng Pharmaceutical was successively rated as a patent demonstration enterprise in Jinhua City and Zhejiang Province. won the third prize of Jinhua Patent Implementation Award in 2013 ; passed the intellectual property management system certification in 2016 and was identified as a national intellectual property advantage enterprise. At present, Jianfeng Pharmaceutical has 140 domestic and foreign applications and 127 registered authorizations for various inventions, utility models and trademark intellectual property rights, including 1 well-known trademarks in China, 2 well-known trademarks in Zhejiang Province and 5 well-known trademarks in Jinhua City. In terms of intellectual property operation, improvement of innovation efficiency, and promotion of ownership and industrialization of innovation achievements, active attempts are also made.
Under normal circumstances, the construction of a national intellectual property advantage enterprise expires for three years, and only after the assessment reaches the standard can it be upgraded to a demonstration enterprise. However, it only took one year for Jianfeng Pharmaceutical to complete the leap from an "advantage enterprise" to a "demonstration enterprise. This indicates that the level of intellectual property creation, management, application and protection of Jianfeng Pharmaceutical has entered a higher level. It is understood that Jianfeng Pharmaceutical has achieved excellent results in the annual assessment of national intellectual property advantage enterprises, which is an important reason for this "jump. Through the implementation of the national standard of "enterprise intellectual property management standard" and the cultivation of advantageous enterprises and demonstration enterprises, Jianfeng pharmaceutical has realized the advanced development of "improving the foundation of intellectual property management, cultivating intellectual property advantages and forming comprehensive competitive advantages". It can not only protect itself, but also avoid infringing on the rights and interests of other enterprises, It provides strong support for the economic transformation and upgrading of enterprises, improving quality and efficiency. In addition, this time it has been identified as a national intellectual property demonstration enterprise, and Jianfeng Pharmaceutical will also receive a 30 yuan award from Jinhua City.
According to the requirements of the documents of the State Intellectual Property Office, the construction period of the national intellectual property demonstration enterprise in 2017 is from 2017 12 to 2020 11 . During this period, local intellectual property management departments should, in accordance with relevant requirements and combined with actual work, explore the establishment of a distinctive enterprise cultivation policy system, further improve the overall plan for the cultivation of demonstration enterprises and advantageous enterprises in the region, and clarify the phased tasks of cultivation. Increase investment, guarantee special funds, gather expert resources and support measures, and strengthen targeted guidance, service, supervision and inspection of enterprise intellectual property work. As a demonstration enterprise, Jianfeng Pharmaceutical will also further formulate a work plan for the construction of demonstration enterprises, establish and improve work leadership and overall coordination mechanisms, further strengthen the management and implementation of intellectual property strategies, increase guarantees, and ensure that the construction of demonstration enterprises achieves practical results and realizes knowledge The development goal of a strong enterprise with property rights. (Reporter Fu Yiwu)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31